• Revenue: US$69.6m (down 14% from 1Q 2024).

• Net loss: US$10.1m (loss widened by US$9.42m from 1Q 2024).

• US$0.081 loss per share (further deteriorated from US$0.006 loss in 1Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 38%.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 4.2% growth forecast for the Personal Products industry in the US.

Performance of the American Personal Products industry.

The company’s shares are up 64% from a week ago.

We should say that we’ve discovered 2 warning signs for Beauty Health (1 is a bit unpleasant!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.